Acceptable diagnostic or predictive test for familial adenomatous polyposis. For classic FAP, consider Familial Adenomatous Polyposis Panel: (APC) Sequencing and Deletion/Duplication, (MUTYH) 2 Mutations (2004915).
Polymerase Chain Reaction/Sequencing
Lavender Lavender (K2EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B).
Transport 3 mL whole blood. (Min: 1 mL)
Ambient: 1 week; Refrigerated: 1 month; Frozen: 6 months
Background Information for Familial Adenomatous Polyposis (APC) Sequencing:
Characteristics of APC-associated Polyposis:
Familial Adenomatous Polyposis (FAP): Development of hundreds to thousands of adenomatous colonic polyps beginning in early adolescence; lifetime risk for cancer is 100 percent. Additional findings may include dental anomalies, polyps of the gastric fundus and duodenum, and congenital hypertrophy of the retinal pigment epithelium (CHRPE).
Attenuated FAP: Fewer colonic adenomatous polyps (average of 30), which are more proximally located and cancer generally occurs at a later age; lifetime risk for cancer is 70 percent.
Gardner syndrome: Multiple colonic adenomatous polyps along with osteomas, desmoid tumors, and soft tissue tumors.
Incidence: Less than 1 percent of colorectal cancer cases.
Inheritance: Autosomal dominant.
Penetrance: Greater than 99 percent in untreated individuals.
Causes: Pathogenic APC allelic variations
Clinical Sensitivity: Approximately 90 percent for classic FAP and less than 30 percent for attenuated FAP.
Methodology: Bidirectional sequencing of the APC coding region and intron-exon boundaries.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Regulatory region mutations, deep intronic mutations, and large deletion/duplications will not be detected. This assay is not designed to detect somatic variants associated with malignancy. Interpretation of this test result may be impacted if the patient has had an allogeneic stem cell transplantation.
Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
|Component Test Code*||Component Chart Name||LOINC|
|2004864||FAP (APC) Sequencing Specimen||31208-2|
|2004865||FAP (APC) Sequencing Interpretation||20990-8|
- APC-Associated Polyposis
- Attenuated FAP
- Gardner Syndrome
- Turcot Syndrome